Treatments for Plaque Psoriasis

Study: Guselkumab More Effective Than Secukinumab in Certain Subpopulations
September 03, 2021

A study published in the Journal of Dermatological Treatment shows guselkumab may be more effective in heavier patients with moderate to severe plaque psoriasis vs secukinumab.

Tremfya Phase 3 Data Show Continued Clearance After 5 Years
April 25, 2021

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

Phase 3 results show risankizumab outperforms secukinumab
January 17, 2020

Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.